Parnax Lab Documents
Documents
0
Ticker
506128.BO
ISIN
INE383L01019
Parnax Lab SEC Filings
Type | Report | Date |
|---|---|---|
| No documents available | ||
Parnax Lab Documents 2026
This page contains all official documents and SEC filings for Parnax Lab stock (506128.BO, ISIN: INE383L01019). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 0 documents are available. Data is updated regularly to provide investors with a complete overview of Parnax Lab's regulatory filings.
Parnax Lab Stock analysis
Parnax Lab Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems.